Drug resistance-related microRNAs in hematological malignancies: Translating basic evidence into therapeutic strategies

Blood Reviews

Volumn 29, Issue 1, 2015, Pages 33-44

  Xie, Lingling ^a   Jing, Rongrong ^a   Qi, Jing ^a   Lin, Zenghua ^a   Ju, Shaoqing ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Biomarkers; Hematological malignancies; MicroRNAs; MiRNAs; Multidrug resistance; Therapeutic targets

Indexed keywords

FAS ASSOCIATED DEATH DOMAIN PROTEIN; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 125B; MICRORNA 128A; MICRORNA 128B; MICRORNA 130B; MICRORNA 138; MICRORNA 155; MICRORNA 17; MICRORNA 17 92; MICRORNA 181A; MICRORNA 181B; MICRORNA 21; MICRORNA 212; MICRORNA 217; MICRORNA 221; MICRORNA 331; MICRORNA 34A; MICRORNA 370; MICRORNA 381; MICRORNA 495; MULTIDRUG RESISTANCE PROTEIN; MYC PROTEIN; MYELOID LEUKEMIA FACTOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CELL CYCLE PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER RESISTANCE; DRUG TARGETING; DRUG TRANSPORT; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; ANIMAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC NEOPLASMS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICRORNAS; RNA, UNTRANSLATED; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MICROENVIRONMENT;

EID: 84921821343     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.09.005     Document Type: Article

References (173)

1. Lawrie C.H. MicroRNAs in hematological malignancies. Blood Rev 2013, 27:143-154.
2. Rancea M., Monsef I., von Tresckow B., Engert A., Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev 2013, 6:CD009411.
3. Reagan J.L., Fast L.D., Safran H., Nevola M., Winer E.S., Castillo J.J., et al. Cellular immunotherapy for refractory hematological malignancies. J Transl Med 2013, 11:150.
4. Di Paola R., Costantini C., Tecchio C., Salvagno G.L., Montemezzi R., Perandini A., et al. Anti-Mullerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies. Oncologist 2013, 18:1307-1314.
5. Zhao D., Jiang Y., Dong X., Liu Z., Qu B., Zhang Y., et al. Arsenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms. Biomed Pharmacother 2011, 65:354-358.
6. Hirose M., Hosoi E., Hamano S., Jalili A. Multidrug resistance in hematological malignancy. J Med Invest 2003, 50:126-135.
7. Ramsay A.D., Rodriguez-Justo M. Chronic lymphocytic leukaemia-the role of the microenvironment pathogenesis and therapy. Br J Haematol 2013, 162:15-24.
8. To K.K. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci 2013, 20:99.
9. Qipshidze-Kelm N., Piell K.M., Solinger J.C., Cole M.P. Co-treatment with conjugated linoleic acid and nitrite protects against myocardial infarction. Redox Biol 2013, 2:1-7.
10. He Y., Jiang X., Chen J. The role of miR-150 in normal and malignant hematopoiesis. Oncogene 2013, 10.1038/onc.2013.346.
11. Cheng J., Guo S., Chen S., Mastriano S.J., Liu C., D'Alessio A.C., et al. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep 2013, 5:471-481.
12. Nishioka C., Ikezoe T., Yang J., Nobumoto A., Tsuda M., Yokoyama A. Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci 2014, 105:297-307.
13. Hong L., Yang Z., Ma J., Fan D. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets 2013, 14:1118-1127.
14. Piecuch A., Oblak E. Yeast ABC proteins involved in multidrug resistance. Cell Mol Biol Lett 2014, 19:1-22.
15. Huang S., Ye J., Yu J., Chen L., Zhou L., Wang H., et al. The accumulation and efflux of lead partly depend on ATP-dependent efflux pump-multidrug resistance protein 1 and glutathione in testis Sertoli cells. Toxicol Lett 2014, 226:277-284.
16. Ingelman-Sundberg M., Zhong X.B., Hankinson O., Beedanagari S., Yu A.M., Peng L., et al. Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos 2013, 41:1725-1731.
17. Feng D.D., Zhang H., Zhang P., Zheng Y.S., Zhang X.J., Han B.W., et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011, 15:2164-2175.
18. Zhao X., Yang L., Hu J., Ruan J. miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010, 34:1078-1082.
19. Xu Y., Ohms S.J., Li Z., Wang Q., Gong G., Hu Y., et al. Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. PLoS One 2013, 8:e82062.
20. Turrini E., Haenisch S., Laechelt S., Diewock T., Bruhn O., Cascorbi I. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics 2012, 22:198-205.
21. Cao B., Li J., Zhu J., Shen M., Han K., Zhang Z., et al. The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity. J Biol Chem 2013, 288:34181-34189.
22. Kant S., Kumar A., Singh S.M. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta 1840, 2014:294-302.
23. Brentnall M., Rodriguez-Menocal L., De Guevara R.L., Cepero E., Boise L.H. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol 2013, 14:32.
24. Tao L.J., Zhou X.D., Shen C.C., Liang C.Z., Liu B., Tao Y., et al. Tetrandrine induces apoptosis and triggers a caspase cascade in U2-OS and MG-63 cells through the intrinsic and extrinsic pathways. Mol Med Rep 2014, 9:345-349.
25. Tatsuta T., Hosono M., Sugawara S., Kariya Y., Ogawa Y., Hakomori S., et al. Sialic acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated mitochondrial perturbation in Jurkat cells. Int J Oncol 2013, 43:1402-1412.
26. Kim J.H., Chae M., Choi A.R., Sik Kim H., Yoon S. SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. Eur J Pharmacol 2014, 723:141-147.
27. Sripayap P., Nagai T., Uesawa M., Kobayashi H., Tsukahara T., Ohmine K., et al. Mechanisms of resistance to azacitidine in human leukemia cell lines. Exp Hematol 2014, 42:294-306. [e2].
28. Lv X.B., Zhang X., Deng L., Jiang L., Meng W., Lu Z., et al. MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim. Cell Biol Int 2014, 38:435-443.
29. Wang L.Q., Kwong Y.L., Kho C.S., Wong K.F., Wong K.Y., Ferracin M., et al. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia-implications on constitutive activation of NFkappaB pathway. Mol Cancer 2013, 12:173.
30. Lee K., Briehl M.M., Mazar A.P., Batinic-Haberle I., Reboucas J.S., Glinsmann-Gibson B., et al. The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies. Free Radic Biol Med 2013, 60:157-167.
31. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102:13944-13949.
32. Humplikova L., Kollinerova S., Papajik T., Pikalova Z., Holzerova M., Prochazka V., et al. Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013, 157:284-293.
33. Allegra D., Bilan V., Garding A., Dohner H., Stilgenbauer S., Kuchenbauer F., et al. Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. Leukemia 2014, 28:98-107.
34. Zenz T., Mohr J., Eldering E., Kater A.P., Buhler A., Kienle D., et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009, 113:3801-3808.
35. Ferracin M., Zagatti B., Rizzotto L., Cavazzini F., Veronese A., Ciccone M., et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer 2010, 9:123.
36. Kim J., Zhang Y., Skalski M., Hayes J., Kefas B., Schiff D., et al. microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. Cancer Res 2014, 74:1541-1553.
37. Moussay E., Palissot V., Vallar L., Poirel H.A., Wenner T., El Khoury V., et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 2010, 9:115.
38. Frenquelli M., Muzio M., Scielzo C., Fazi C., Scarfo L., Rossi C., et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010, 115:3949-3959.
39. Fonte E., Apollonio B., Scarfo L., Ranghetti P., Fazi C., Ghia P., et al. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clin Cancer Res 2013, 19:367-379.
40. Zhu D.X., Zhu W., Fang C., Fan L., Zou Z.J., Wang Y.H., et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 2012, 33:1294-1301.
41. Li H., Hui L., Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai) 2012, 44:269-277.
42. Bai H., Cao Z., Deng C., Zhou L., Wang C. miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol 2012, 138:595-602.
43. Hickey C.J., Schwind S., Radomska H.S., Dorrance A.M., Santhanam R., Mishra A., et al. Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood 2013, 121:159-169.
44. Havelange V., Ranganathan P., Geyer S., Nicolet D., Huang X., Yu X., et al. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood 2014, 123:2412-2415.
45. Liu L., Chen R., Huang S., Wu Y., Li G., Zhang B., et al. miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med Oncol 2012, 29:243-247.
46. Liang H., Li X., Wang L., Yu S., Xu Z., Gu Y., et al. MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells. Cell Physiol Biochem 2013, 32:1818-1829.
47. Mosakhani N., Raty R., Tyybakinoja A., Karjalainen-Lindsberg M.L., Elonen E., Knuutila S. MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res 2013, 141:272-276.
48. Schotte D., De Menezes R.X., Akbari Moqadam F., Khankahdani L.M., Lange-Turenhout E., Chen C., et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011, 96:703-711.
49. Mei Y., Gao C., Wang K., Cui L., Li W., Zhao X., et al. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci 2014, 105:463-472.
50. Li X.J., Luo X.Q., Han B.W., Duan F.T., Wei P.P., Chen Y.Q. MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer 2013, 109:2189-2198.
51. Zeng C.W., Zhang X.J., Lin K.Y., Ye H., Feng S.Y., Zhang H., et al. Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways. Mol Pharmacol 2012, 81:578-586.
52. Ghaffari S.H., Bashash D., Dizaji M.Z., Ghavamzadeh A., Alimoghaddam K. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumour Biol 2012, 33:157-172.
53. Zhang H., Luo X.Q., Feng D.D., Zhang X.J., Wu J., Zheng Y.S., et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 2011, 10:108.
54. Gocek E., Wang X., Liu X., Liu C.G., Studzinski G.P. MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res 2011, 71:6230-6239.
55. Meng H.T., Zhu L., Ni W.M., You L.S., Jin J., Qian W.B. Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-kappaB activity and miR-16-1*. Acta Pharmacol Sin 2011, 32:503-511.
56. Flamant S., Ritchie W., Guilhot J., Holst J., Bonnet M.L., Chomel J.C., et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010, 95:1325-1333.
57. Bose P., Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk Res Rep 2013, 2:12-14.
58. Weber A., Auslander D., Hacker G. Mouse Noxa uses only the C-terminal BH3-domain to inactivate Mcl-1. Apoptosis 2013, 18:1093-1105.
59. Wang J., Yang B., Han L., Li X., Tao H., Zhang S., et al. Demethylation of miR-9-3 and miR-193a genes suppresses proliferation and promotes apoptosis in non-small cell lung cancer cell lines. Cell Physiol Biochem 2013, 32:1707-1719.
60. Ji F., Zhang H., Wang Y., Li M., Xu W., Kang Y., et al. MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone 2013, 56:220-226.
61. Gong J., Zhang J.P., Li B., Zeng C., You K., Chen M.X., et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013, 32:3071-3079.
62. Kim J.H., Kim W.S., Park C. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma 2012, 53:1586-1591.
63. Zimmerman E.I., Dollins C.M., Crawford M., Grant S., Nana-Sinkam S.P., Richards K.L., et al. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol 2010, 78:811-817.
64. Lu F., Zhang J., Ji M., Li P., Du Y., Wang H., et al. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol 2014, 45:383-392.
65. Mosakhani N., Mustjoki S., Knuutila S. Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. Mol Cytogenet 2013, 6:27.
66. Joshi D., Chandrakala S., Korgaonkar S., Ghosh K., Vundinti B.R. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene 2014, 542:109-112.
67. Liu J., Chen G., Feng L., Zhang W., Pelicano H., Wang F., et al. Loss of p53 and altered miR15-a/16-1short right arrowMCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia 2014, 28:118-128.
68. Bean G.R., Ganesan Y.T., Dong Y., Takeda S., Liu H., Chan P.M., et al. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal 2013, 6:ra20.
69. Plotz M., Gillissen B., Quast S.A., Berger A., Daniel P.T., Eberle J. The BH3-only protein Bim(L) overrides Bcl-2-mediated apoptosis resistance in melanoma cells. Cancer Lett 2013, 335:100-108.
70. Harada M., Pokrovskaja-Tamm K., Soderhall S., Heyman M., Grander D., Corcoran M. Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia. Leuk Lymphoma 2012, 53:2041-2050.
71. Firatligil B., Biray Avci C., Baran Y. miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells. J BUON 2013, 18:437-441.
72. Molitoris J.K., McColl K.S., Distelhorst C.W. Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17-92 contributes to the induction of Bim and initiation of apoptosis. Mol Endocrinol 2011, 25:409-420.
73. Rao E., Jiang C., Ji M., Huang X., Iqbal J., Lenz G., et al. The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012, 26:1064-1072.
74. Todoerti K., Barbui V., Pedrini O., Lionetti M., Fossati G., Mascagni P., et al. Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 2010, 95:260-269.
75. Yang A., Ma J., Wu M., Qin W., Zhao B., Shi Y., et al. Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies. Leuk Lymphoma 2012, 53:2465-2473.
76. Li Y., Zhu X., Gu J., Hu H., Dong D., Yao J., et al. Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 2010, 15:215-221.
77. Li Y., Zhu X., Gu J., Dong D., Yao J., Lin C., et al. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 2010, 101:948-954.
78. Gu J., Zhu X., Li Y., Dong D., Yao J., Lin C., et al. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol 2011, 28:211-218.
79. Liu L., Wang S., Chen R., Wu Y., Zhang B., Huang S., et al. Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun 2012, 425:368-373.
80. Rottmann S., Luscher B. The Mad side of the Max network: antagonizing the function of Myc and more. Curr Top Microbiol Immunol 2006, 302:63-122.
81. Reuss D.E., Mucha J., Hagenlocher C., Ehemann V., Kluwe L., Mautner V., et al. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS. PLoS One 2013, 8:e57152.
82. Manfe V., Biskup E., Willumsgaard A., Skov A.G., Palmieri D., Gasparini P., et al. cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas. PLoS One 2013, 8:e59390.
83. Yan Z.X., Wu L.L., Xue K., Zhang Q.L., Guo Y., Romero M., et al. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 2014, 28:880-887.
84. Bai H., Xu R., Cao Z., Wei D., Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 2011, 585:402-408.
85. Bai H., Wei J., Deng C., Yang X., Wang C., Xu R. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 2013, 97:223-231.
86. Li H., Hui L., Xu W., Shen H., Chen Q., Long L., et al. Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Pharm Biol 2012, 50:1233-1240.
87. Sun H.J., Meng L.Y., Shen Y., Zhu Y.Z., Liu H.R. S-benzyl-cysteine-mediated cell cycle arrest and apoptosis involving activation of mitochondrial-dependent caspase cascade through the p53 pathway in human gastric cancer SGC-7901 cells. Asian Pac J Cancer Prev 2013, 14:6379-6384.
88. Hassan Z.K., Elamin M.H., Omer S.A., Daghestani M.H., Al-Olayan E.S., Elobeid M.A., et al. Oleuropein induces apoptosis via the p53 pathway in breast cancer cells. Asian Pac J Cancer Prev 2013, 14:6739-6742.
89. Hoffmann G., Breitenbucher F., Schuler M., Ehrenhofer-Murray A.E. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem 2014, 289:5208-5216.
90. Manfe V., Biskup E., Rosbjerg A., Kamstrup M., Skov A.G., Lerche C.M., et al. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PLoS One 2012, 7:e29541.
91. Murray M.Y., Rushworth S.A., Zaitseva L., Bowles K.M., Macewan D.J. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle 2013, 12:2144-2153.
92. Sanchez-Espiridion B., Martin-Moreno A.M., Montalban C., Figueroa V., Vega F., Younes A., et al. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol 2013, 162:336-347.
93. Ranjan K., Surolia A., Pathak C. Apoptotic potential of Fas-associated death domain on regulation of cell death regulatory protein cFLIP and death receptor mediated apoptosis in HEK 293T cells. J Cell Commun Signal 2012, 6:155-168.
94. Yamada N., Noguchi S., Kumazaki M., Shinohara H., Miki K., Naoe T., et al. Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD). Biochim Biophys Acta 1843, 2014:590-602.
95. Boni V., Bitarte N., Cristobal I., Zarate R., Rodriguez J., Maiello E., et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010, 9:2265-2275.
96. Shah M.A., Schwartz G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001, 7:2168-2181.
97. Salerno E., Scaglione B.J., Coffman F.D., Brown B.D., Baccarini A., Fernandes H., et al. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol Cancer Ther 2009, 8:2684-2692.
98. Kotani A., Ha D., Hsieh J., Rao P.K., Schotte D., den Boer M.L., et al. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 2009, 114:4169-4178.
99. Kotani A., Ha D., Schotte D., den Boer M.L., Armstrong S.A., Lodish H.F. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle 2010, 9:1037-1042.
100. Akbari Moqadam F., Lange-Turenhout E.A., Aries I.M., Pieters R., den Boer M.L. MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk Res 2013, 37:1315-1321.
101. Wierstra I. The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res 2013, 118:97-398.
102. Alvarez-Fernandez M., Medema R.H. Novel functions of FoxM1: from molecular mechanisms to cancer therapy. Front Oncol 2013, 3:30.
103. Zhou M., Zeng J., Wang X., Guo Q., Huang T., Shen H., et al. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1. J Transl Med 2013, 11:265.
104. Kullmann M.K., Grubbauer C., Goetsch K., Jakel H., Podmirseg S.R., Trockenbacher A., et al. The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle 2013, 12:2625-2635.
105. Garbrecht M.R., Schmidt T.J. Expression and regulation of 11-beta hydroxysteroid dehydrogenase type 2 enzyme activity in the glucocorticoid-sensitive CEM-C7 human leukemic cell line. ISRN Oncol 2013, 2013:245246.
106. Dejean C., Richard D. Mechanisms of action of glucocorticoids. Rev Med Interne 2013, 34:264-268.
107. Ma L., Fang M., Liang Y., Xiang Y., Jia Z., Sun X., et al. Low expression of glucocorticoid receptor alpha isoform in adult immune thrombocytopenia correlates with glucocorticoid resistance. Ann Hematol 2013, 92:953-960.
108. Schlossmacher G., Stevens A., White A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 2011, 211:17-25.
109. Manenschijn L., van den Akker E.L., Lamberts S.W., van Rossum E.F. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 2009, 1179:179-198.
110. Tessel M.A., Benham A.L., Krett N.L., Rosen S.T., Gunaratne P.H. Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer 2011, 2:182-189.
111. Huang X., Yang M., Jin J. Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs. Leuk Lymphoma 2012, 53:1188-1195.
112. Lv M., Zhang X., Jia H., Li D., Zhang B., Zhang H., et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-alpha and cAMP/PKA pathways. Leukemia 2012, 26:769-777.
113. Rainer J., Ploner C., Jesacher S., Ploner A., Eduardoff M., Mansha M., et al. Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia 2009, 23:746-752.
114. Chen C.F., He X., Arslan A.D., Mo Y.Y., Reinhold W.C., Pommier Y., et al. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIalpha and drug responsiveness. Mol Pharmacol 2011, 79:735-741.
115. Liu Y.P., Chen H.L., Tzeng C.C., Lu P.J., Lo C.W., Lee Y.C., et al. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells. Breast Cancer Res Treat 2013, 138:383-393.
116. Ganapathi R.N., Ganapathi M.K. Mechanisms regulating resistance to inhibitors of topoisomerase II. Front Pharmacol 2013, 4:89.
117. Castells M., Thibault B., Delord J.P., Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci 2012, 13:9545-9571.
118. Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med 2012, 18:1332-1334.
119. Boyerinas B., Zafrir M., Yesilkanal A.E., Price T.T., Hyjek E.M., Sipkins D.A. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 2013, 121:4821-4831.
120. Shain K.H., Tao J. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene 2013, 10.1038/onc.2013.379.
121. Li Z.W., Dalton W.S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006, 20:333-342.
122. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
123. Melo S.A., Kalluri R. miR-29b moulds the tumour microenvironment to repress metastasis. Nat Cell Biol 2013, 15:139-140.
124. Chou J., Shahi P., Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 2013, 12:3262-3271.
125. Lwin T., Lin J., Choi Y.S., Zhang X., Moscinski L.C., Wright K.L., et al. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 2010, 116:5228-5236.
126. Lwin T., Zhao X., Cheng F., Zhang X., Huang A., Shah B., et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 2013, 123:4612-4626.
127. Bianchi G., Kumar S., Ghobrial I.M., Roccaro A.M. Cell trafficking in multiple myeloma. Open J Hematol 2012, 3(Suppl 1). [pii: 4].
128. Markovina S., Callander N.S., O'Connor S.L., Xu G., Shi Y., Leith C.P., et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer 2010, 9:176.
129. Fowler J.A., Mundy G.R., Lwin S.T., Edwards C.M. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 2012, 72:2183-2189.
130. Xu G., Liu K., Anderson J., Patrene K., Lentzsch S., Roodman G.D., et al. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood 2012, 119:4205-4214.
131. Hao M., Zhang L., An G., Sui W., Yu Z., Zou D., et al. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol 2011, 4:37.
132. Hao M., Zhang L., An G., Meng H., Han Y., Xie Z., et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011, 52:1787-1794.
133. Tian Z., Zhao J.J., Tai Y.T., Amin S.B., Hu Y., Berger A.J., et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 2012, 120:3958-3967.
134. Wang X., Li C., Ju S., Wang Y., Wang H., Zhong R. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma 2011, 52:1991-1998.
135. Munker R., Liu C.G., Taccioli C., Alder H., Heerema N. MicroRNA profiles of drug-resistant myeloma cell lines. Acta Haematol 2010, 123:201-204.
136. Xiong Q., Zhong Q., Zhang J., Yang M., Li C., Zheng P., et al. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J Proteome Res 2012, 11:2078-2090.
137. Leone E., Morelli E., Di Martino M.T., Amodio N., Foresta U., Gulla A., et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013, 19:2096-2106.
138. Hu H.Y., Li K.P., Wang X.J., Liu Y., Lu Z.G., Dong R.H., et al. Set9, NF-kappaB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells. Acta Pharmacol Sin 2013, 34:157-166.
139. Luo X., Gu J., Zhu R., Feng M., Zhu X., Li Y., et al. Integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma cells in response to berberine. BMC Syst Biol 2014, 8:82.
140. Peled A., Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics 2013, 3:34-39.
141. Sison E.A., Rau R.E., McIntyre E., Li L., Small D., Brown P. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol 2013, 160:785-797.
142. Chen Y., Jacamo R., Konopleva M., Garzon R., Croce C., Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest 2013, 123:2395-2407.
143. Yu Y., Yang L., Zhao M., Zhu S., Kang R., Vernon P., et al. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 2012, 26:1752-1760.
144. Yu Y., Cao L., Yang L., Kang R., Lotze M., Tang D. microRNA 30A promotes autophagy in response to cancer therapy. Autophagy 2012, 8:853-855.
145. Seca H., Lima R.T., Lopes-Rodrigues V., Guimaraes J.E., Almeida G.M., Vasconcelos M.H. Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets 2013, 14:1135-1143.
146. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675.
147. Fang C., Zhu D.X., Dong H.J., Zhou Z.J., Wang Y.H., Liu L., et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 2012, 91:553-559.
148. Tanaka M., Oikawa K., Takanashi M., Kudo M., Ohyashiki J., Ohyashiki K., et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009, 4:e5532.
149. Zuo Z., Calin G.A., de Paula H.M., Medeiros L.J., Fernandez M.H., Shimizu M., et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 2011, 118:413-415.
150. Kaddar T., Chien W.W., Bertrand Y., Pages M.P., Rouault J.P., Salles G., et al. Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. Leuk Res 2009, 33:1217-1223.
151. Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008, 105:15535-15540.
152. Navarro A., Diaz T., Martinez A., Gaya A., Pons A., Gel B., et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009, 114:2945-2951.
153. Scholl V., Hassan R., Zalcberg I.R. miRNA-451: a putative predictor marker of Imatinib therapy response in chronic myeloid leukemia. Leuk Res 2012, 36:119-121.
154. Lopotova T., Zackova M., Klamova H., Moravcova J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?. Leuk Res 2011, 35:974-977.
155. Wang Y., Ji P., Liu J., Broaddus R.R., Xue F., Zhang W. Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 2009, 8:8.
156. Dai C.W., Bai Q.W., Zhang G.S., Cao Y.X., Shen J.K., Pei M.F., et al. MicroRNA let-7f is down-regulated in patients with refractory acute myeloid leukemia and is involved in chemotherapy resistance of adriamycin-resistant leukemic cells. Leuk Lymphoma 2014, 55:1645-1648.
157. Huang J.J., Yu J., Li J.Y., Liu Y.T., Zhong R.Q. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol 2012, 29:2402-2408.
158. Moussay E., Wang K., Cho J.H., van Moer K., Pierson S., Paggetti J., et al. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2011, 108:6573-6578.
159. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
160. Yan J., Jiang N., Huang G., Tay J.L., Lin B., Bi C., et al. Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. Br J Haematol 2013, 163:93-103.
161. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010, 13:57-66.
162. San Jose-Eneriz E., Roman-Gomez J., Jimenez-Velasco A., Garate L., Martin V., Cordeu L., et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer 2009, 8:69.
163. Fan Y., Shen B., Tan M., Mu X., Qin Y., Zhang F., et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J 2014, 281:1750-1758.
164. Jiang M., Huang O., Xie Z., Wu S., Zhang X., Shen A., et al. A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol 2014, 87:254-283.
165. Liu Z., Sun M., Lu K., Liu J., Zhang M., Wu W., et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One 2013, 8:e77293.
166. Yang Y., Li H., Hou S., Hu B., Liu J., Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013, 8:e65309.
167. Huber-Keener K.J., Liu X., Wang Z., Wang Y., Freeman W., Wu S., et al. Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data. PLoS One 2012, 7:e41333.
168. Zhao H., Zhang X., Frazao J.B., Condino-Neto A., Newburger P.E. HOX antisense lincRNA HOXA-AS2 is an apoptosis repressor in all trans retinoic acid treated NB4 promyelocytic leukemia cells. J Cell Biochem 2013, 114:2375-2383.
169. Morceau F., Chateauvieux S., Gaigneaux A., Dicato M., Diederich M. Long and short non-coding RNAs as regulators of hematopoietic differentiation. Int J Mol Sci 2013, 14:14744-14770.
170. Han B.W., Feng D.D., Li Z.G., Luo X.Q., Zhang H., Li X.J., et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 2011, 20:4903-4915.
171. Garofalo M., Croce C.M. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 2013, 16:47-59.
172. Chen L., Jiang K., Jiang H., Wei P. miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. Exp Ther Med 2014, 8:527-532.
173. Sotillo E., Laver T., Mellert H., Schelter J.M., Cleary M.A., McMahon S., et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011, 30:2587-2594.